CD3ε | Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

885 results for “CD3ε”

Trials

View all 422 →

A Phase 1 Trial of CD33xCD3 BsAb in Pediatric Patients With Relapsed or Refractory Acute Myeloid Leukemia

3 participants · First posted Oct 14, 2021

XmAb18968 (CD3-CD38) in Relapsed or Refractory Acute Leukemia and T Cell Lymphoblastic Leukemia

22 participants · First posted Sep 9, 2021

Study of ISB 1342, a CD38/CD3 Bispecific Antibody, in Subjects With Previously Treated Multiple Myeloma

81 participants · First posted Oct 13, 2017

Drugs

View all 423 →

anti-CD38/BCMA/CD3 trispecific antibody (Jiangsu hengrui)

CD39 (Amgen)

CD38-077

News

View all 40 →

BioAtla Secures $22.5 Million Flexible Financing to Support Operations While Pursuing Strategic Partnership

Novel Bispecific Antibody Shows Promise for Autoimmune Disease Treatment in Preclinical Studies

BioAtla Initiates Strategic Review Process Amid Major Restructuring and 70% Workforce Reduction

Page 1 of 89